Reuters logo
Actelion gets go-ahead to continue new drug trial
May 8, 2013 / 5:16 AM / 5 years ago

Actelion gets go-ahead to continue new drug trial

ZURICH, May 8 (Reuters) - Actelion should continue a late-stage study into a new heart and lung drug, independent monitors have recommmended, with final results now expected by mid-2014, giving the biotech firm hope it has a further product in its pipeline.

Actelion said in a statement the Independent Data Monitoring Committee had told the company it had unanimously recommended the continuation of a late-stage study in selexipag with no modifications, adding final results should come next year.

Selexipag is the third drug from Actelion to treat pulmonary arterial hypertension (PAH), a progressively worsening condition characterised by abnormally high blood pressure in the arteries of the lungs. The cause is unknown and the disease has no cure. (Reporting by Caroline Copley)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below